Compare CAVA Group Inc (CAVA) vs Core Scientific Inc (CORZ) Price & Performance

CAVA stock surged 12.32% to $69.165, driven by strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. Despite a bearish technical signal, fundamentals show robust expansion with same-store sales up 9% and net income margin at 4.79%. Analyst consensus remains strongly bullish with a $89.75 price target, though high valuations like a P/E of 108.59 pose concerns.

Outlook is positive due to earnings momentum and market share gains, but risks include valuation sensitivity and competitive pressures. Investors should weigh growth potential against premium multiples, with institutional support underscoring long-term confidence amid near-term volatility.

Core Scientific (CORZ) trades at $21.18, up 8.95% in the last session, amid a technical bearish trend but strong analyst optimism. The company reported Q2 2026 revenue growth and a strategic AMD partnership for AI infrastructure, though it faces significant net losses and negative cash flow. Key support lies at $18, with resistance near $21.

The outlook is mixed: bullish analyst targets near $36 suggest upside potential from AI-driven contracts, but high cash burn and persistent losses pose risks. Investors should weigh growth prospects against financial sustainability, with sentiment hinging on execution of new deals and margin improvement.